metastatic

Stemline Therapeutics, a subsidiary of the Menarini Group, receives US FDA approval for ORSERDUTM (elacestrant) as the first and only treatment specifically indicated for patients with ESR1 mutations in ER+, HER2-advanced or metastatic breast cancer

ESR1 mutations are present in up to 40% of ER+, HER2- advanced or metastatic breast cancer. ESR1 mutations are a known driver of resistance to standard endocrine therapy and have so far been difficult to treat. ORSERDU is the first endocrine innovation in more than 20 years to specifically address ESR1 mutations, a major unmet […]

Treatment decision making among patients with metastatic prostate cancer: impact of decision locus of control on functional outcomes and decision satisfaction

American Cancer Society. Cancer facts and figures 2022. Atlanta: American Cancer Society; 2022. Oswald LB, Schumacher FA, Gonzalez BD, Moses KA, Penson DF, Morgans AK. What do men with metastatic prostate cancer consider when making treatment decisions? A mixed methods study. Patient prefers adherence. 2020;14:1949–59. Google Scholar Article Elkin EB, Kim SHM, Casper ES, Kissane […]

Susan G. Komen® applauds the House’s introduction of the bipartisan Metastatic Breast Cancer Access to Care Act

Urges Senate action, prompt passage to provide immediate relief to thousands WASHINGTON, 27 January 2023 /PRNewswire/ — Susan G. Komen®, the world’s leading breast cancer organization, applauds House lawmakers for their leadership on bipartisan legislation that would make financial benefits and health insurance immediately available to people living with metastatic breast cancer. In 117th In […]

Susan G. Komen® applauds the House’s introduction of the bipartisan Metastatic Breast Cancer Access to Care Act

Urges Senate action, prompt passage to provide immediate relief to thousands WASHINGTON, 27 January 2023 /PRNewswire/ — Susan G. Komen®, the world’s leading breast cancer organization, applauds House lawmakers for their leadership on bipartisan legislation that would make financial benefits and health insurance immediately available to people living with metastatic breast cancer. In 117th In […]

Positive CHMP opinion for darolutamide in combination with docetaxel for the treatment of hormone-sensitive metastatic prostate cancer

ORION CORPORATION PRESS RELEASE January 27, 2023 at 14:00 EET Positive CHMP opinion for darolutamide in combination with docetaxel for the treatment of hormone-sensitive metastatic prostate cancer The CHMP recommendation is based on data from the Phase III ARASENS study, which demonstrated that androgen deprivation therapy (ADT) with darolutamide in combination with docetaxel significantly reduced […]

European Commission approves Trastuzumab Deruxtecan for HER2-low metastatic breast cancer

Fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) received approval in the European Union as a single agent for the treatment of patients with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy for metastatic disease or have developed disease recurrence during or within six months of completing adjuvant chemotherapy.1 Approval was based on findings from the […]

NAPOLI-3 results support NALIRIFOX for metastatic pancreatic cancer

Combination treatment with liposomal irinotecan, 5-fluorouracil, leucovorin and oxaliplatin (NALIRIFOX) outperformed treatment with nab-paclitaxel and gemcitabine (Gem-NabP) in patients with metastatic pancreatic ductal adenocarcinoma in the NAPOLI-3 study. NALIRIFOX improved progression-free survival (PFS) and overall survival (OS), compared to Gem-NabP, for patients who had not received prior treatment in the metastatic setting. These results were […]

Frontline Liposomal Irinotecan/NALIRIFOX Produces OS Benefits in Metastatic Pancreatic Ductal Adenocarcinoma

First-line treatment with the combination of liposomal irinotecan (Onivyde) plus 5-fluorouracil (5-FU), leucovorin and oxaliplatin (NALIRIFOX) produced clinically significant and statistically significant improvement in overall survival (OS) and progression-free survival (PFS) vs nab-paclitaxel (Abraxane) plus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma (PDAC), according to the results of the phase 3 study NAPOLI 3 […]

Scroll to top